Chemomab Therapeutics surges after changes to clinical programs

Chemomab Therapeutics

09/03/2022 13:51

** U.S.-listed shares of Israeli biopharmaceutical company
 CMMB.O  surge nearly 13% to $4.10 premarket
    ** Announces revisions to clinical programs for lead
candidate CM-101 by expanding mid-stage trial to treat primary
sclerosing cholangitis, a rare chronic liver disease
 urn:newsml:reuters.com:*:nPn6yNsr1a
    ** Adds it is also working with experts on finalizing design
of another mid-stage study for CM-101 in systemic sclerosis, an
autoimmune disease, to expedite some data
    ** "Changes also expected to extend cash runway through end
of 2023," says CMMB; cash and cash equivalents were at $61.2
million as of Dec. 31
    ** All three brokerages covering CMMB rate stock "buy" or
higher; their median PT is $30
    ** Stock had fallen 47% YTD up to last close

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))